Skip to main content
SpringerLink
Log in

Successful discontinuation of eculizumab therapy in a patient with aHUS

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Campistol JM, Arias M, Ariceta G et al (2013) An update for atypical haemolytic uraemic syndrome: diagnosis and treatment: a consensus document. Nefrologia 33(1):27–45. doi:10.3265/Nefrologia.pre2012.Nov.11781

    PubMed  Google Scholar 

  2. Legendre CM, Licht C, Muus P et al (2013) Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. NEJM 368:2169–2181. doi:10.1056/NEJMoa1208981

    Article  CAS  PubMed  Google Scholar 

  3. Laurence J (2012) Atypical hemolytic uremic syndrome (aHUS): making the diagnosis. Clin Adv Hematol Oncol 10:1–12

    PubMed  Google Scholar 

  4. Frimat M, Tabarin F, Dimitrov JD et al (2013) Complement activation by heme as a secondary hit for atypical hemolytic uremic syndrome. Blood 122(2):282–292. doi:10.1182/blood-2013-03-489245

    Article  CAS  PubMed  Google Scholar 

  5. Ohanian M, Cable C, Halka K (2011) Reduced dose maintenance eculizumab in atypical uremic syndrome (aHUS): an update on a previous case report. Clin Pharmacol 3:45–50. doi:10.2147/CPAA.S23687

    CAS  PubMed Central  PubMed  Google Scholar 

  6. Parker C (2009) Eculizumab for paroxysmal nocturnal haemoglobinuria. Lancet 373:759–767. doi:10.1016/S0140-6736(09)60001-5

    Article  CAS  PubMed  Google Scholar 

  7. Châtelet V, Lobbedez T, Frémeaux-Bacchi V, Ficheux M, Ryckelynck JP, Hurault de Ligny B (2010) Eculizumab: safety and efficacy after 17 months of treatment in a renal transplant patient with recurrent atypical hemolytic uremic syndrome: case report. Transplant Proc 42:4353–4355. doi:10.1016/ j.transproceed. 2010.09. 125

    Article  PubMed  Google Scholar 

  8. Davin JC, Gracchi V, Bouts A, Groothoff J, Strain L, Goodship T (2010) Maintenance of kidney function following treatment with eculizumab and discontinuation of plasma exchange after a third kidney transplant for atypical hemolytic uremic syndrome associated with a CFH mutation. Am J Kidney Dis 55:708–711. doi:10.1053/j.ajkd.2009.08.01

    Article  PubMed  Google Scholar 

  9. Prescott HC, Wu HM, Cataland SR, Baiocchi RA (2010) Eculizumab therapy in an adult with plasma-exchange refractory atypical hemolytic uremic syndrome. Am J Hematol 85:976–977. doi:10.1002/ajh.21862

    Article  PubMed  Google Scholar 

  10. Hillmen P, Muus P, Röth A et al (2013) Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol 162(1):62–73. doi:10.1111/bjh.12347

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflict of interest.

ᅟ

An informed consent was obtained from the patient being included in this study. Details that might disclose the identity of the subject under study have been omitted.

Author information

Authors and Affiliations

  1. Penn State Hershey Cancer Institute, Penn State Hershey Medical Center, Penn State University College of Medicine, 500 University Drive, Hershey, PA, 17033, USA

    Jeffrey J. Pu & Abigail Sido

  2. Division of Hematology, Johns Hopkins Medical Institutions, Baltimore, MD, 21205, USA

    Jeffrey J. Pu

Authors
  1. Jeffrey J. Pu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Abigail Sido
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jeffrey J. Pu.

Additional information

Statement: This “Letter to the editor” reports and discusses an interesting aHUS patient case. This retrospective patient case study has been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. All procedures followed this study were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pu, J.J., Sido, A. Successful discontinuation of eculizumab therapy in a patient with aHUS. Ann Hematol 93, 1423–1425 (2014). https://doi.org/10.1007/s00277-013-1972-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-013-1972-1

Keywords

Search

Navigation